Flush on the success of its mRNA vaccine for COVID-19, BioNTech SE is already planning for the next stage of its business life with the acquisition of the neoantigen T-cell receptor (TCR) R&D program and manufacturing plant from Gilead Sciences, Inc.’s Kite Pharma division. The deal is part of a broader expansion of its oncology development program – which has already shown early signs of progress in the clinic – and global manufacturing footprint.
BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets
German Biotech Sets Sights On Cancer Cell Therapies
The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.